Optimizing Stroke Prophylaxis of Acute Atrial Fibrillation with an Electronic Clinical Decision Support Tool: A Stepped-Wedge Cluster Randomized Trial Design

使用电子临床决策支持工具优化急性心房颤动的中风预防:阶梯楔形集群随机试验设计

基本信息

  • 批准号:
    10415095
  • 负责人:
  • 金额:
    $ 29.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

Abstract Statement Atrial fibrillation (AF) is the most common arrhythmia in the world, with significant morbidity and mortality. With appropriate oral anticoagulation, the risk of stroke due to atrial fibrillation decreases by 64%. Although atrial fibrillation is commonly diagnosed and treated in the Emergency Department (ED), oral anticoagulation is significantly underprescribed. Underprescribing has been attributed to a lack of empowerment and deferral of prescribing to longitudinal care clinicians. However, patients often do not follow-up with longitudinal care clinicians, resulting in missed opportunities to provide guideline-recommended care. Our proposal focuses on this missed opportunity to change the trajectory of care in the ED for patients with atrial fibrillation with appropriate early prescribing of oral anticoagulants, and thereby, improve clinical outcomes. This R01 Physician-Scientist Early Investigator proposal is in keeping with the mission of NHLBI "to promote the prevention and treatment of heart disease … and enhance the health of all individuals so that they can live longer and more fulfilling lives." We leverage an existing outpatient shared-decision making clinical decision support tool to improve stroke prevention for patients with atrial fibrillation and test its ability to improve guideline-recommended care in the acute care setting of the Emergency Department—a fast-paced, episodic, high-intensity environment. Electronic health record clinical decision support (CDS) tools have emerged as a means to guide clinicians on best practices and can make a significant impact on clinical outcomes. By increasing guideline adherence and improving the transition of care from the ED to the outpatient setting, this proposal could significantly reduce the risk of stroke for patients with atrial fibrillation with an intervention that could be rapidly and effectively disseminated across other settings. The project is a convergent parallel quantitative-qualitative study (mixed-methods) consisting of three components: (1) Implement a clinical decision support tool in a multi-centered stepped-wedge cluster randomized trial, (2) Identify clinician facilitators and barriers to ideal AF care and refine CDS tools for different settings using qualitative approaches, and (3) Explore patient satisfaction with the tool for future scalability and generalizability. This research will allow Dr. Kea to gain knowledge on how the unique environments of each hospital setting interacts with the CDS tool and how to refine the tool for large-scale dissemination, including rural and resource-poor environments, on a national scale.
摘要陈述 心房颤动(AF)是世界上最常见的心律失常,具有显着的发病率和死亡率。和 适当的口服抗凝药物,因房颤引起的中风风险降低64%。虽然心房 颤动通常在急诊科 (ED) 进行诊断和治疗,口服抗凝药物是 处方明显不足。处方不足的原因是缺乏授权和推迟 向纵向护理临床医生开处方。然而,患者通常不会进行纵向护理随访 临床医生,导致错过提供指南推荐护理的机会。我们的建议重点是 这错失了改变急诊室对心房颤动患者护理轨迹的机会 适当的早期处方口服抗凝剂,从而改善临床结果。这个R01 医师-科学家早期研究者的提案符合 NHLBI 的使命“促进 预防和治疗心脏病……并增强所有人的健康,使他们能够生存 更长、更充实的生活。”我们利用现有的门诊共享决策来制定临床决策 改善房颤患者中风预防的支持工具并测试其改善能力 急诊科急症护理环境中指南推荐的护理——快节奏、间歇性、 高强度环境。电子健康记录临床决策支持 (CDS) 工具已成为一种 旨在指导临床医生采用最佳实践,并对临床结果产生重大影响。经过 提高指南的遵守率并改善从急诊室到门诊的护理过渡,这 该提案可以通过以下干预措施显着降低房颤患者中风的风险: 可以在其他环境中快速有效地传播。该项目是一个收敛并行 定量-定性研究(混合方法)由三个部分组成:(1)实施临床 多中心阶梯楔形集群随机试验中的决策支持工具,(2) 识别临床医生 理想 AF 护理的促进因素和障碍,并使用定性方法针对不同设置完善 CDS 工具 方法,(3) 探索患者对该工具的满意度,以实现未来的可扩展性和普遍性。 这项研究将使 Kea 博士了解每个医院环境的独特环境如何 与 CDS 工具交互以及如何完善该工具以进行大规模传播,包括农村和农村地区 全国范围内资源匮乏的环境。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bory Kea其他文献

Bory Kea的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bory Kea', 18)}}的其他基金

Optimizing Stroke Prophylaxis of Acute Atrial Fibrillation with an Electronic Clinical Decision Support Tool: A Stepped-Wedge Cluster Randomized Trial Design
使用电子临床决策支持工具优化急性心房颤动的中风预防:阶梯楔形集群随机试验设计
  • 批准号:
    10197697
  • 财政年份:
    2021
  • 资助金额:
    $ 29.7万
  • 项目类别:
Optimizing Stroke Prophylaxis of Acute Atrial Fibrillation with an Electronic Clinical Decision Support Tool: A Stepped-Wedge Cluster Randomized Trial Design
使用电子临床决策支持工具优化急性心房颤动的中风预防:阶梯楔形集群随机试验设计
  • 批准号:
    10627824
  • 财政年份:
    2021
  • 资助金额:
    $ 29.7万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 29.7万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了